Abstract
Atrial tachyarrhythmias (ATAs) lead to clinical deterioration and worsening heart failure (HF) in patients with acute decompensated HF (ADHF). We evaluated the effects of the ultrashort-acting intravenous β1-blocker landiolol on the heart rate, hemodynamics, and outcome in patients with ATAs and ADHF. A total of 67 consecutive hospitalized patients with ATAs and ADHF who were treated with landiolol (36 males, 67 ± 12 years) were included in this single-center retrospective study. The primary endpoints were changes in heart rate and systolic blood pressure from baseline during intravenous landiolol administration. The secondary endpoints included restoration of sinus rhythm and outcomes. The median maintenance dose of intravenous landiolol was 3.0 (range 1.0-12.0) μg/kg/min and the median treatment duration was 5 (range 1-24) days. Intravenous landiolol reduced heart rate (141 ± 17 beats/min at baseline to 99 ± 20 beats/min at 6 h, P < 0.001) without a marked reduction in blood pressure or deterioration of HF. During landiolol treatment, 15 (22%) patients had spontaneously restored sinus rhythm. Eight patients experienced in-hospital death, and 41 (69%) were discharged with sinus rhythm. During the follow-up of 16 ± 12 months, p...Continue Reading
References
Jun 1, 1992·Chemical & Pharmaceutical Bulletin·S IguchiM Kawamura
Jul 1, 1991·Circulation·H R MiddlekauffL W Stevenson
May 1, 1997·European Heart Journal·H J CrijnsD J Van Veldhuisen
Apr 1, 1997·Heart·M P Van den BergK I Lie
Sep 16, 1998·Circulation·E J BenjaminD Levy
Aug 5, 2000·European Heart Journal·H J CrijnsD J van Veldhuisen
Nov 8, 2001·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·J SasaoH Goto
Feb 11, 2003·Critical Care Medicine·Andreas MayrWalter Hasibeder
May 29, 2003·Circulation·Thomas J WangEmelia J Benjamin
Jun 16, 2004·Circulation·Yong-Mei ChaBernard J Gersh
Sep 3, 2005·The Journal of Clinical Investigation·Michael Rubart, Douglas P Zipes
May 2, 2009·Journal of the American College of Cardiology·Robby NieuwlaatHarry J G M Crijns
Jun 14, 2013·Drugs·Greg L Plosker
Jun 27, 2013·Heart and Vessels·Toru AdachiKazutaka Aonuma
Dec 4, 2013·Cardiology·Shigeki KobayashiMasafumi Yano
Jan 23, 2014·International Journal of Cardiology·Shuchita Gupta, Vincent M Figueredo
Apr 26, 2014·Circulation Research·Peng-Sheng ChenStanley Nattel
Aug 6, 2015·Circulation. Heart Failure·Shi-Jun LiMichael Fu
Apr 20, 2016·Journal of Arrhythmia·Yuko WadaHisao Ogawa
May 22, 2016·European Heart Journal·Piotr PonikowskiUNKNOWN ESC Scientific Document Group
Feb 23, 2018·Drugs·Yahiya Y Syed
Apr 7, 2018·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Tuoyo O Mene-AfejukuGerald Pekler
Sep 7, 2018·European Heart Journal Supplements : Journal of the European Society of Cardiology·Stephan von HaehlingOlivier Bouvet
Sep 7, 2018·European Heart Journal Supplements : Journal of the European Society of Cardiology·Hans DomanovitsGünter Stix
Citations
Mar 7, 2020·International Heart Journal·Wojciech DabrowskiAndrzej Jaroszynski
Jul 16, 2020·ESC Heart Failure·Teruhiko Imamura, Koichiro Kinugawa
Apr 21, 2020·Vascular Health and Risk Management·Yujiro MatsuishiYoshiaki Inoue
Jul 5, 2021·Heart Failure Reviews·Grigorios TsigkasPeriklis Davlouros